Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology

Recent & Breaking News (NDAQ:PCYC)

Robbins Arroyo LLP: Acquisition of Pharmacyclics, Inc. (PCYC) by AbbVie Inc. (ABBV) May Not Be in Shareholders' Best Interests

PR Newswire March 5, 2015

SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Pharmacyclics, Inc. - PCYC

PR Newswire March 5, 2015

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie -- PCYC

Business Wire March 5, 2015

AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

PR Newswire March 4, 2015

Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases

PR Newswire February 27, 2015

In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

PR Newswire February 27, 2015

Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates

PR Newswire February 18, 2015

IMBRUVICA® (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

PR Newswire February 17, 2015

Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results

PR Newswire February 12, 2015

U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)

PR Newswire January 29, 2015

Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook

PR Newswire January 12, 2015

IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

PR Newswire January 5, 2015

Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission

PR Newswire December 22, 2014

Pharmacyclics Named 2014 Outstanding Company by BayBio

PR Newswire December 12, 2014

IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

PR Newswire December 8, 2014

Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

PR Newswire December 8, 2014

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

PR Newswire December 8, 2014

Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)

GlobeNewswire December 8, 2014

IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

PR Newswire December 6, 2014

Pharmacyclics Announces Launch of informCLL(TM) Registry for Chronic Lymphocytic Leukemia (CLL) Patients

PR Newswire December 5, 2014